Impact of menopausal hormone therapy on the development and progression of cervical and endometrial cancers
- Autores: Yakushevskaya O.V.1, Babaeva N.A.1, Yureneva S.V.1, Ashrafyan L.A.1
-
Afiliações:
- Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
- Edição: Nº 8 (2022)
- Páginas: 30-35
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249486
- DOI: https://doi.org/10.18565/aig.2022.8.30-35
- ID: 249486
Citar
Texto integral
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Palavras-chave
Texto integral
Sobre autores
Oksana Yakushevskaya
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: aluckyone777@gmail.com
Ph.D., Researcher at the Department of Gynecological Endocrinology
Nataliya Babaeva
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: natbabaeva@yandex.ru
Dr. Med. Sci., Oncologist, Oncological Department of Surgical Methods of Treatment, Leading Researcher, Institute of Oncogynecology and Mammology
Svetlana Yureneva
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: syureneva@gmail.com
Dr. Med. Sci., Leading Researcher of the Department of Gynecological Endocrinology
Levon Ashrafyan
Academician V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia
Email: levaa2004@yahoo.com
Academician of the RAS, Dr. Med. Sci., Professor, Director of the Institute of Oncogynecology and Mammology
Bibliografia
- Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6): 394-424. https://dx.doi.org/10.3322/caac.21492.
- Arbyn M., Weiderpass E., Bruni L., de Sanjose S., Saraiya M., Ferlay J. et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob. Health. 2020; 8(2): e191-e203. https://dx.doi.org/10.1016/S2214-109X(19)30482-6.
- National Cancer Institute. Surveillance, Epidemiology and End Results Program. Cancer stat facts: cervical cancer. Available at: https://seer.cancer.gov/statfacts/html/cervix.html (Accessed November 11, 2018).
- Abu-Rustum N.R., Yashar C.M., Bean S., Bradley K., Campos S.M., Chon H.S. et al. NCCN guidelines insights: cervical cancer, version 1.2020: featured updates to the NCCN guidelines. J. Natl. Compr. Canc. Netw. 2020; 18(6): 660-6. https://dx.doi.org/10.6004/jnccn.2020.0027.
- Шабалова О.В., Юренева С.В., Ермакова Е.И., Хохлова С.В., Гарданова Ж.Р., Якушевская О.В. Хирургическая менопауза как фактор риска раннего развития коморбидных состояний у женщин репродуктивного возраста. Акушерство и гинекология. 2021; 6: 54-9. [Shabalova O.V., Yureneva S.V., Ermakova E.I., Khokhlova S.V., Gardanova Zh.R., Yakushevskaya O.V. Surgical menopause as a risk factor for the early development of comorbid conditions in reproductive-aged women. Obstetrics and Gynecology. 2021; 6: 54-9. (in Russian)]. https://dx.doi.org/10.18565/aig.2021.6.54-59.
- Якушевская О.В., Юренева С.В., Протасова А.Э., Хабас Г.Н., Думановская М.Р. Менопаузальная гормональная терапия и рак тела матки: допустимость тандема. Гинекология. 2018; 20(6): 42-7. [Yakushevskaya O.V., Yureneva S.V., Protasova A.E., Khabas G.N., Dumanovskaya M.R. Menopausal hormone therapy and uterine cancer: the asseptability of the tandem. Gynecology. 2018; 20(6): 42-7. (in Russian)]. https://dx.doi.org/10.26442/20795696.2018.6.180113.
- Zhai Y., Bommer G.T., Feng Y., Wiese A.B., Fearon E.R., Cho K.R. Loss of estrogen receptor 1 enhances cervical cancer invasion. American Journal of Pathology. 2010; 177(2): 884-95. https://dx.doi.org/10.2353/ajpath.2010.091166).
- Rauh L.A., Pannone A.F., Cantrell L.A. Hormone replacement therapy after treatment for cervical cancer: are we adhering to standard of care? Gynecol. Oncol. 2017; 147(3): 597-600. https://dx.doi.org/10.1016/j.ygyno.2017.09.009.
- Якушевская О.В., Юренева С.В., Хабас Г.Н., Протасова А.Э. Менопаузальная гормональная терапия и рак шейки матки: современный взгляд на проблему. Акушерство и гинекология. 2017; 11: 148-53. [Yakushevskaya O.V., Yureneva S.V., Khabas G.N., Protasova A.E. Menopausal hormone therapy and cervical cancer: A current view of the problem. Obstetrics and Gynecology. 2017; 11: 148-53. (in Russian)]. https://dx.doi.org/10.18565/aig.2017.11.148-153.
- Vargiu V., Amar I.D., Rosati A., Dinoi G., Turco L.C., Capozzi V.A. et al. Hormone replacement therapy and cervical cancer: a systematic review of the literature. Climacteric. 2021; 24(2): 120-7. https://dx.doi.org/10.1080/13697137.2020.18264260.
- Persson I., Yuen J., Bergkvist L., Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int. J. Cancer. 1996; 67(3): 327-32. https://dx.doi.org/10.1002/(SICI)1097-0215(19960729)67:3<327::AID-IJC4>3.0.C0;2-T.
- Schneider C., Jick S.S., Meier C.R. Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations. Climacteric. 2009; 12(6): 514-24. https://dx.doi.org/10.3109/13697130903075352.
- Roura E., Travier N., Waterboer T., de Sanjose S., Bosch F.X., Pawlita M. et al. The influence of hormonal factors on the risk of developing cervical cancer and pre-cancer: results from the EPIC Cohort. PLoS One. 2016; 11(1): e0147029. https://dx.doi.org/10.1371/journal.pone.0147029.
- Bristol M.L., James C.D., Wang X., Fontan C.T., Morgan I.M. Estrogen attenuates the growth of human papillomavirus-positive epithelial cells. mSphere. 2020; 5(2): e00049-20. https://dx.doi.org/10.1128/mSphere.00049-20.
- Ploch E. Hormonal replacement therapy in patients after cervical cancer treatment. Gynecol. Oncol. 1987; 26(2): 169-77. https://dx.doi.org/10.1016/0090-8258(87)90270-8.
- Gadduccia A., Cosio S., Fuzzetti F. Estro-progestin contraceptives and risk of cervical cancer: a debated issue. Anticancer Res. 2020; 40(11): 5995-6002. https://dx.doi.org/10.21873/anticanres.14620.
- Asthana S., Busa V., Labani S. Oral contraceptives use and risk of cervical cancer - a systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2020; 247: 163-75. https://dx.doi.org/10.1016/j.ejogrb.2020.02.014.
- Frega A., Scardamaglia P., Piazze J., Cerekja A., Pacchiarotti A., Verrico M., Moscarini M. Oral contraceptives and clinical recurrence of human papillomavirus lesions and cervical intraepithelial neoplasia following treatment. Int. J. Gynaecol. Obstet. 2008; 100(2): 175-8. https://dx.doi.org/10.1016/j.ijgo.2007.08.023.
- Lacey J.V. Jr., Brinton L.A., Barnes W.A., Gravitt P.E., Greenberg M.D., Hadjimichael O.C. et al. Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix. Gynecol. Oncol. 2000; 77(1): 149-54. https://dx.doi.org/10.1006/gyno.2000.5731.
- Richardson A., Watson L., Persic M., Phillips A. Safety of hormone replacement therapy in women with a history of cervical adenocarcinoma. Post Reprod. Health. 2021; 27(3): 167-73. https://dx.doi.org/10.1177/20533691211028518.
- Jaakkola S., Pukkala E., Lyytinen H.K., Ylikorkala O. Postmenopausal estradiol-progestagen therapy and risk for uterine cervical cancer. Int. J. Cancer. 2012; 131(4): E537-43. https://dx.doi.org/10.1002/ijc.27321.
- Rodolakis A., Biliatis I., Morice P., Reed N., Mangier M., Kesic V., Denschlag D. European Society of Gynecological Oncology Task Force for Fertility Preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients. Int. J. Gynecol. Cancer. 2015; 25(7): 1258-65. https://dx.doi.org/10.1097/IGC.0000000000000493.
- Deli T., Orosz M., Jacab A. Hormone replacement therapy in cancer survivors - review of the literature. Pathol. Oncol. Res. 2020; 26(1): 63-78. https://dx.doi.org/10.1007/s12253-018-00569-x.
- Barakat R.R., Bundy B.N., Spirtos N.M., Bell J., Mannel R.S.; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I. or II endometrial cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 2006; 24(4): 587-92. https://dx.doi.org/10.1200/JCO.2005.02.8464.
- Shim S.H., Lee S.J., Kim S.N. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur. J. Cancer. 2014; 50(9): 1628-37. https://dx.doi.org/10.1016/j.ejca.2014.03.006.
- Mitra S., Lami M.S., Ghosh A., Das R., Tallei T.K., Fatimawali et al. Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications? Cancers (Basel). 2022; 14(3): 759. https://dx.doi.org/10.3390/cancers14030759.
- Bodner K., Laubichler P., Kimberger O., Czerwenka K., Zeillinger R., Bodner-Adler B. Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res. 2010; 30(4): 1341-5.
- Martin J.D., Hahnel R., McCartney A.J., De Klerk N. The influence of estrogen and progesterone receptors on survival in patients with carcinoma of the uterine cervix. Gynecol. Oncol. 1986; 23(3): 329-35. https://dx.doi.org/10.1016/0090-8258(86)90134-4.
- Smith E.M., Levy B.T., Ritchie J.M., Jia J., Wang D., Haugen T.H., Turek L.P. Is use of hormone replacement therapy associated with increased detection of human papillomavirus and potential risk of HPV-related genital cancers? Eur. J. Cancer Prev. 2002; 11(3): 295-305. https://dx.doi.org/10.1097/00008469-200206000-00013.
- Smith E.M., Ritchie J.M., Levy B.T., Zhang W., Wang D., Haugen T.H., Turek L.P. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detect. Prev. 2003; 27(6): 472-80. https://dx.doi.org/10.1016/s0361-090x(03)00104-1.